344079-M

Flurbiprofen

A mixture of S(+) and R(-) enantiomers.

• Sinonimo/i: Flurbiprofen, (±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
• Formula empirica (notazione di Hill): C₁₅H₁₃FO₂
• Numero CAS: 5104-49-4
• Peso molecolare: 244.26
• Numero MDL: MFCD00079303
• Codice UNSPSC: 12352200

Proprietà

• Livello qualitativo: 100
• Saggio: ≥98% (HPLC)
• Forma fisica: solid
• Produttore/marchio commerciale: Calbiochem^®
• Condizioni di stoccaggio: OK to freeze
• Colore: white
• Solubilità: DMSO: 50 mg/mL
• Temperatura di conservazione: 10-30°C
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18); SYTBZMRGLBWNTM-UHFFFAOYSA-N

Descrizione

Descrizione generale

A mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.

A mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice

Azioni biochim/fisiol

Primary Target
Cyclooxygenase

Target IC₅₀: 5 nM for LPS-induced COX

Attenzione

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

Ricostituzione

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.

Altre note

Jantzen, P.T., et al. 2002. J. Neurosci.22, 2246.
Hinz, R., et al. 2001. Pharmacol. Res.18, 151.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Range, S.P., et al. 2000. Eur. Respir. J.15, 751.
van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther.16, 353.
Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther.282, 339.
Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol.75, 1088.
Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.

Note legali

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informazioni sulla sicurezza

• Pittogrammi: GHS06
• Avvertenze: Danger
• Indicazioni di pericolo: H301
• Consigli di prudenza: P264 - P270 - P301 + P310 - P405 - P501
• Classi di pericolo: Acute Tox. 3 Oral
• Codice della classe di stoccaggio: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe di pericolosità dell'acqua (WGK): WGK 3
• Punto d’infiammabilità (°F): Not applicable
• Punto d’infiammabilità (°C): Not applicable